Search clinical trials for: apatinib

Total 2171 results

Binkui Li

Recruiting

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Yunfei Yuan

Recruiting

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
Hebei Medical University

Unknown

Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Gastroesophageal Junction Adenocarcinoma

China
The Second Hospital of Hebei Medical University

Unknown

TMZ Plus Apatinib in Newly Diagnosed High-grade Glioma：RCT

Glioma

China
GlaxoSmithKline

Completed

Pharmacokinetics And Pharmacodynamics Of Lapatinib In Two Dosing Regimens In Treatment-naive Patients With Breast Cancer

Neoplasms, Breast

United States, Israel
Indiana University
GlaxoSmithKline

Terminated

Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast

Ductal Carcinoma in Situ

United States
GlaxoSmithKline

Withdrawn

A Phase I Study to Test Alternate Oral Formulations vs the Current Tablet Formulation of Lapatinib

Healthy Subjects

United States
University Hospital, Bordeaux

Terminated

A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy (LAPAINBLAD)

Bladder Carcinoma | Cystectomy | Infiltrative Bladder Carcinoma

France
GlaxoSmithKline

Completed

GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer

Neoplasms, Breast

Japan
Medical University of South Carolina
Boehringer Ingelheim

Withdrawn

A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer

United States
University of Alabama at Birmingham
GlaxoSmithKline; AbbVie; Breast Cancer Research Foundation of Alabama

Active, not recruiting

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Metastatic Triple Negative Breast Cancer

United States
Cancer Institute and Hospital, Chinese Academy...

Completed

Apatinib Combined With Oral Etoposide in Metastatic HER2 Negative Breast Cancer

Breast Cancer

China
GlaxoSmithKline

Completed

A Study to Examine the Effects of Esomeprazole on the Pharmacokinetics of Orally Administered Lapatinib in Subjects With Metastatic ErbB2 Positive Breast Cancer

Neoplasms, Breast

United States, Korea, Republic of, Spain
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Neoplasms, Breast

United Kingdom, United States, Peru, Israel, Poland, Russian Federation, Korea, Republic of, Thailand, Pakistan, Hungary, India, Canada, France, Mexico, Malaysia, Singapore
Timothy Burns, MD, PHD
Novartis

Withdrawn

Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations

Non-small Cell Lung Cancer

United States
Hutchison Medipharma Limited

Unknown

HMPL-813 in Treating Patients With Glioblastoma

Glioblastoma

China
Novartis Pharmaceuticals

Withdrawn

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung Cancer
Benazir Bhutto Hospital, Rawalpindi

Completed

Comparing the Outcome in Patients of Acute Pancreatitis, With and Without Prophylactic Antibiotics

Acute Pancreatitis

Pakistan
Bristol-Myers Squibb

Completed

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

Pharmacokinetic Study in Healthy Participants

United States
Nanfang Hospital, Southern Medical University

Not yet recruiting

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer Extensive Stage
China Medical University, China

Recruiting

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

Gastric Cancer | AFP

China
Qilu Pharmaceutical Co., Ltd.

Unknown

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Non-small-cell Lung Cancer

China
Peking University Cancer Hospital & Institute

Unknown

Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma

Melanoma
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy | Gastrict Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

Gastric Cancer

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial...

Active, not recruiting

PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer

Colorectal Cancer | Microsatellite Instability High

China
Shenzhen People's Hospital

Unknown

Apatinib Combined With EGFR-TKI for Advanced Slow-progressed EGFR-TKI Resistant NSCLC (AFLC)

NSCLC | Apatinib | EGFR-TKI

China
Universitätsklinikum Hamburg-Eppendorf
Boehringer Ingelheim

Terminated

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Refractory Cancer

Germany
Baylor Breast Care Center
GlaxoSmithKline

Completed

Neoadjuvant GW572016 to Treat Breast Cancer (GW)

Breast Cancer

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group

Completed

Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme

Brain and Central Nervous System Tumors

Canada
Li Huiping

Not yet recruiting

A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast Cancer

Advanced Breast Cancer
Boehringer Ingelheim

Completed

Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung Adenocarcinoma

Non-squamous, Non-Small Cell Lung Cancer

Japan
Boehringer Ingelheim

No longer available

Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)

Solid Tumors
University of Kansas Medical Center

Terminated

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Metastatic Breast Cancer

United States
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
UNC Lineberger Comprehensive Cancer Center
GlaxoSmithKline

Completed

Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy (NRR)

Prostate Cancer

United States
Boehringer Ingelheim

Completed

A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Arbeitsgemeinschaft medikamentoese Tumortherapie
GlaxoSmithKline

Terminated

Lapatinib Plus Caelyx in Patients With Advanced Metastatic Breast Cancer Following Failure of Trastuzumab Therapy

Metastatic Breast Cancer

Austria
Boehringer Ingelheim

Terminated

Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.

Neoplasms

United States, Taiwan
National Health Research Institutes, Taiwan
China Medical University Hospital; Chang Gung Memorial Hospital; Kaohsiung Medical... and other collaborators

Enrolling by invitation

BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study) (BEAR)

Esophageal Squamous Cell Carcinoma (ESCC)

Taiwan
GlaxoSmithKline

Completed

Exploratory Lapatinib (Positron Emission Tomography) PET Study in Subjects With Breast Cancer

Cancer

United Kingdom
GlaxoSmithKline

Completed

Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer

Neoplasms, Breast

United States, Australia, Germany, Hungary, Poland, Peru, France, Israel, Russian Federation, Spain, Canada, Denmark, Hong Kong, Latvia, Korea, Republic of, China, Belgium, Philippines, Italy, United Kingdom, Argentina, India, New Zealand and more
Sheba Medical Center

Unknown

An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

NSCLC

Israel
Novartis Pharmaceuticals

Available

Treatment Plan CINC280A02001M to Provide Access to Capmatinib, for MET Exon 14 Skipping Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer | Nonsmall Cell Lung Cancer | Carcinoma, Non-Small Cell Lung | Non-Small-Cell Lung Carcinoma
Novartis Pharmaceuticals

Active, not recruiting

Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC (Geometry-N)

Non-small Cell Lung Cancer

United States
Intergroupe Francophone de Cancerologie Thoracique
Novartis

Completed

RW Effectiveness of Capmatinib in Advanced MET-dysregulated NSCLC Included in the French Compassionate Use Program (ATU) (CapmATU)

Non Small Cell Lung Cancer | MET Alterations | METex14 Mutations

France
Massachusetts General Hospital
Novartis

Completed

A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

Malignant Non-small Cell Neoplasm of Lung Stage IV

United States
Zhongshan Hospital Xiamen University

Recruiting

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Ovarian Cancer

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma (IMplus)

Head and Neck Squamous Cell Carcinoma

China

3

Subscribe